<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574144</url>
  </required_header>
  <id_info>
    <org_study_id>READMIT-HF</org_study_id>
    <nct_id>NCT01574144</nct_id>
  </id_info>
  <brief_title>REducing 30-day ADMIssions in posT-discharge Subjects (READMIT)</brief_title>
  <acronym>READMIT-HF</acronym>
  <official_title>Observational Study of Reducing 30-day Admissions in Post-discharge Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to collect and characterize multiple physiologic
      data from a broad subset of subjects with acute heart failure (HF)

      Changes in physiologic data are expected to correlate with 30-day readmission rates in this
      population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, non-randomized feasibility study aimed at obtaining data from
      systolic and diastolic HF subjects in the hospital, with continued monitoring using an
      external wearable monitor for up to 4 weeks post-hospital-discharge. Data will be collected
      during the hospital stay and at in office follow-up visits at 1 week and 1 month
      post-hospital discharge

      The data will help generate hypotheses and aid in determining whether development of a
      detection algorithm for acute heart failure decompensation is feasible. Due to the
      feasibility nature of this study there is no minimum required sample size but it is
      anticipated that the study will enroll up to 100 subjects from seven (7) study sites in the
      United States and one (1) study site in Australia

      The study objectives are:

        -  Collect and characterize physiologic data from subjects with acute decompensated heart
           failure.

        -  Characterization of data related to health care utilizations within 30-days
           Post-discharge

        -  Correlation between patch monitor collected data and inpatient clinical data

        -  Correlation between patch monitor data and other clinical data collected after patient
           discharge (30-60 days)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Health Care Utilizations</measure>
    <time_frame>30 days post-discharge</time_frame>
    <description>Percentage of Participants with health care utilizations. Healthcare utilizations include hospitalizations, urgent care visits and emergency department visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight Per Unit Change in Thoracic Impedance</measure>
    <time_frame>Discharge to 30 days post discharge</time_frame>
    <description>Change in body weight per unit change in thoracic impedance. The regression coefficients between body weight and thoracic impedance.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>AVIVO™ PiiX Patch Monitor System</arm_group_label>
    <description>Heart failure patients monitored continuously for 30 days post-discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVIVO™ PiiX Patch Monitor System</intervention_name>
    <description>External monitoring for 30 days post-discharge.</description>
    <arm_group_label>AVIVO™ PiiX Patch Monitor System</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Heart failure patients who are admitted to the hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with acute decompensated heart failure

          -  Subject (or legal guardian) willing to give consent for their participation

          -  Subject ≥18 years of age

        Exclusion Criteria:

          -  Subject who is expected to receive a heart transplant or a ventricular assist device
             within 6 months

          -  Subject who cannot tolerate placement of external patch monitor on chest in the
             proposed location (ECG Lead II orientation)

          -  Subject with known allergies or hypersensitivities to adhesives or hydrogels

          -  Subject with implantable devices with active minute ventilation sensors.

          -  Subject who will not comply to study protocol requirements. This includes completing
             required data collection, and attending required follow up study visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>READMIT-HF Study Team</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Cardiology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33511-5908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Heart and Cardiovascular</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102-2568</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mohawk Valley Heart Institute</name>
      <address>
        <city>Utica</city>
        <state>New York</state>
        <zip>13501-5930</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219-2364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>April 3, 2012</study_first_submitted>
  <study_first_submitted_qc>April 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <results_first_submitted>February 12, 2014</results_first_submitted>
  <results_first_submitted_qc>February 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2018</results_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AVIVO™ PiiX Patch Monitor System</title>
          <description>Heart failure patients monitored continuously for 30 days post-discharge.
AVIVO™ PiiX Patch Monitor System: External monitoring for 30 days post-discharge.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrollment</population>
      <group_list>
        <group group_id="B1">
          <title>AVIVO™ PiiX Patch Monitor System</title>
          <description>Heart failure patients monitored continuously for 30 days post-discharge.
AVIVO™ PiiX Patch Monitor System: External monitoring for 30 days post-discharge.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Health Care Utilizations</title>
        <description>Percentage of Participants with health care utilizations. Healthcare utilizations include hospitalizations, urgent care visits and emergency department visits.</description>
        <time_frame>30 days post-discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AVIVO™ PiiX Patch Monitor System</title>
            <description>Heart failure patients monitored continuously for 30 days post-discharge.
AVIVO™ PiiX Patch Monitor System: External monitoring for 30 days post-discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Health Care Utilizations</title>
          <description>Percentage of Participants with health care utilizations. Healthcare utilizations include hospitalizations, urgent care visits and emergency department visits.</description>
          <units>percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="18.4" upper_limit="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight Per Unit Change in Thoracic Impedance</title>
        <description>Change in body weight per unit change in thoracic impedance. The regression coefficients between body weight and thoracic impedance.</description>
        <time_frame>Discharge to 30 days post discharge</time_frame>
        <population>All subjects with changes of body weight and impedance from discharge to 30 days post discharge.</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure Patients Monitored Continuously With AVIVO PiiX</title>
            <description>AVIVO™ PiiX Patch Monitor System: External monitoring from enrollment to discharge: regression coefficient</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight Per Unit Change in Thoracic Impedance</title>
          <description>Change in body weight per unit change in thoracic impedance. The regression coefficients between body weight and thoracic impedance.</description>
          <population>All subjects with changes of body weight and impedance from discharge to 30 days post discharge.</population>
          <units>lbs/Ohm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.15" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment to 3 months post-discharge</time_frame>
      <desc>An adverse event (AE) is considered a serious AE if it
Lead to death OR
Lead to a serious deterioration in subject's health (life threatening illness/injury, permanent impairment of body, hospitalization/prolonged, medical/surgical intervention to prevent the previously mentioned conditions) OR
Lead to fetal distress/death/defect</desc>
      <group_list>
        <group group_id="E1">
          <title>AVIVO™ PiiX Patch Monitor System</title>
          <description>Heart failure patients monitored continuously for 30 days post-discharge.
AVIVO™ PiiX Patch Monitor System: External monitoring for 30 days post-discharge.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fribrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardiac Failure congrestive</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HyperKalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Bruise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Application Site Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Thyroid Stimlating Hormone Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Lautenbach</name_or_title>
      <organization>Medtronic, Inc</organization>
      <phone>7633609163</phone>
      <email>amy.a.lautenbach@medtronic.com@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

